IDXG — Interpace Biosciences Cashflow Statement
0.000.00%
Last trade - 00:00- $6.06m
- $11.91m
- $40.21m
- 61
- 99
- 68
- 90
Annual cashflow statement for Interpace Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K/A | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -26.7 | -26.5 | -14.9 | -22 | 0.802 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 5.65 | 1.71 | 1.63 | 14.8 | 2.04 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -2.41 | 5.23 | -0.819 | -3.05 | -0.083 |
| Change in Accounts Receivable | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -19 | -14 | -8.72 | -7.69 | 3.79 |
| Capital Expenditures | -0.131 | -1.57 | -0.354 | -0.322 | -0.47 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -13.8 | 0 | 0.039 | 6.53 | 0.383 |
| Acquisition of Business | |||||
| Sale of Business | |||||
| Sale of Fixed Assets | |||||
| Cash from Investing Activities | -13.9 | -1.57 | -0.315 | 6.21 | -0.087 |
| Financing Cash Flow Items | -6.02 | 0 | -8.36 | 0 | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 29.2 | 16.6 | 8.98 | 3 | -5.03 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -3.75 | 1.05 | -0.058 | 1.51 | -1.33 |